Calendrier de promotion NervGen Pharma Corp.
Calendrier prolongé
Calendrier simple
Les principaux paramètres
La monnaie du rapport
usd
Grade
Sous-estimation
| Nom |
Signification |
Grade |
| P/S |
0 |
0 |
| P/BV |
85.59 |
1 |
| P/E |
0 |
0 |
Efficacité
| Nom |
Signification |
Grade |
| ROA |
-146.73 |
0 |
| ROE |
-8460.2 |
0 |
| ROIC |
0 |
0 |
Dividendes
| Nom |
Signification |
Grade |
| Rendement des dividendes |
0 |
0 |
| DSI |
0 |
0 |
| La croissance moyenne des dividendes |
0 |
0 |
Devoir
| Nom |
Signification |
Grade |
| Debt/EBITDA |
0 |
10 |
| Debt/Ratio |
0 |
10 |
| Debt/Equity |
6.89 |
0 |
Pouls de croissance
| Nom |
Signification |
Grade |
| Revenus, milliards, % |
0 |
0 |
| Ebitda, % |
1369.23 |
10 |
| EPS, % |
-14.88 |
0 |
Prix
|
Prix |
Min. |
Max. |
Changement |
Changements dans l'industrie |
Changements dans l'index |
| Hier |
2.73 $ |
0 $ |
0 $ |
+0.3663 % |
0 % |
0 % |
| Semaine |
2.85 $ |
0 $ |
0 $ |
-3.86 % |
0 % |
0 % |
| Mois |
3.72 $ |
0 $ |
0 $ |
-26.34 % |
0 % |
0 % |
| 3 mois |
2.02 $ |
2.11 $ |
4.72 $ |
+35.44 % |
0 % |
0 % |
| Six mois |
2.02 $ |
1.81 $ |
4.72 $ |
+35.71 % |
0 % |
0 % |
| Année |
2.04 $ |
1.46 $ |
4.72 $ |
+34.31 % |
0 % |
0 % |
| 3 ans |
1.49 $ |
1.12 $ |
4.72 $ |
+83.89 % |
0 % |
0 % |
| 5 ans |
1.29 $ |
0.945 $ |
4.72 $ |
+112.4 % |
0 % |
0 % |
| 10 ans |
0.66 $ |
0.66 $ |
4.72 $ |
+413.64 % |
0 % |
0 % |
| Année à ce jour |
2.1 $ |
1.81 $ |
4.72 $ |
+30.48 % |
0 % |
0 % |
Entreprises similaires
P/E & P/BVEV/Ebitda & Debt/Ebitda
La gestion de l'entreprise
| Superviseur |
Titre d'emploi |
Paiement |
Année de naissance |
| Mr. William Joseph Radvak BASc |
Co-Founder & Advisor |
44.12k |
1963 (62 années) |
| Dr. Harold Martin Punnett D.M.D. |
Co-Founder & Independent Director |
N/A |
|
| Dr. Daniel D. Mikol M.D., Ph.D. |
Chief Medical Officer |
583.89k |
|
| Mr. Michael Kelly |
CEO, President & Director |
544.43k |
1966 (59 années) |
| Mr. Brian McAlister |
Co-Founder & Advisor |
N/A |
|
| Mr. William J. Adams C.A., CPA, CA, CPA |
CFO & Corporate Secretary |
|
1962 (63 années) |
| Dr. Charles V. Olson D.Sc. |
Senior Vice President of Technical Operations |
|
1957 (68 années) |
| Ms. Elizabeth Eberhardt B.Sc. |
Senior Vice President of Program Management |
|
|
Informations sur l'entreprise
À propos de l'entreprise NervGen Pharma Corp.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
MAX Chat
